secwatch.observer — SEC 8-K summary
======================================

Issuer:     SWK Holdings Corp (SWKHL)
CIK:        0001089907
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001628280-24-047913
Event type: earnings
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SWK Holdings Reports Q3 2024 Net Income of $3.5 Million, Revenue Up 15.6%
-------------------------------------------------------------------------

- Q3 2024 GAAP net income was $3.5 million, compared to $4.5 million in Q3 2023.
- Total revenue increased 15.6% to $10.4 million, driven by finance receivables segment.
- Net finance receivables grew 14.4% to $255.9 million as of September 30, 2024.
- Closed $11.0 million royalty financing with Relief Therapeutics and $25.7 million amendment with Eton Pharmaceuticals.
- GAAP book value per share rose 3.7% to $22.94; repurchased ~340,000 shares YTD for $5.8 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1089907/000162828024047913/0001628280-24-047913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1089907/000162828024047913/swkh-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer